ESPE2024 Poster Category 1 Pituitary, Neuroendocrinology and Puberty 1 (9 abstracts)
1The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China. 2Shaoxing People’s Hospital, Shaoxing, China. 3Zhejiang Provincial Center for Maternal, child and Reproductive Health, Hangzhou, China
Aim: Aromatase inhibitors are widely used in clinical practice and are currently employed in the treatment of adolescents with short stature. However, the impact of these inhibitors on the reproductive function in male adolescents remains unclear.
Methods: The data of patient with short stature who had completed aromatase inhibition therapy between 2015 and 2022 at the First Affiliated Hospital of Zhejiang University School of Medicine. A follow-up was conducted in 2023 to evaluate semen parameters and retrospectively gather data on sex hormones, complications, and other relevant factors during the treatment period.
Results: Ten patients fulfilled the inclusion criteria and agreed to participate in the follow-up. Nine patients completed the collection of semen and blood samples, while one patient only provided blood samples. The average treatment duration was 1.93 years (1.0, 3.5yrs), with an initial treatment age of 12.7years (10, 16yrs). The average sperm density was 78.17million/ml (9.59, 223.88million/ml), average acrosome integrity was 75.71% (30.9%,93.4%), and DNA Fragmentation Index was 15.39% (8.62, 25.72). All patients maintained sex hormone levels within the normal range, and the majority exhibited normal semen analysis results.
Conclusion: The use of aromatase inhibitors during adolescence appears to have no adverse effects on adult reproductive function.